Isomorphic Labs raises $2.1bn Series B for AI drug design

Beijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

Tokyo software company developing sales AI agents, an agent operating platform and consulting services for enterprise sales teams.